Epidemiology of meningococcal disease in Latin America: Current situation and opportunities for prevention

Neurological Research

Volumn 32, Issue 3, 2010, Pages 263-271

  Sáfadi, Marco Aurélio Palazzi ^a,b   Cintra, Otávio Augusto Leite ^c  

^a Santa Casa de Sao Paulo School of Medicine   (Brazil)

^b Hospital Sao Luiz   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Epidemiology; Meningococcus; Neisseria meningiditis; Serogroup; Surveillance

Indexed keywords

CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; DEXAMETHASONE; FUROSEMIDE; MANNITOL; MENINGOCOCCUS VACCINE; MENINGOCOCCUS VACCINE PLUS DIPHTHERIA TOXIN; MENINGOCOCCUS VACCINE PLUS TETANUS TOXOID; MENITORIX; PEARLITOL; PENICILLIN G; PENICILLIN G POTASSIUM; RECOMBINANT VACCINE; RIFAMPICIN; UNCLASSIFIED DRUG;

APLASTIC ANEMIA; ARGENTINA; BONE MARROW DEPRESSION; BRAZIL; CHEMOPROPHYLAXIS; CHILE; COLOMBIA; COST EFFECTIVENESS ANALYSIS; DRUG CONJUGATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; INCIDENCE; INFECTION RATE; INTRACRANIAL HYPERTENSION; MEDLINE; MENINGITIS; MENINGOCOCCOSIS; MEXICO; NEISSERIA MENINGITIDIS; NONHUMAN; PREVENTIVE HEALTH SERVICE; REVIEW; SINGLE DRUG DOSE; SOUTH AND CENTRAL AMERICA; URUGUAY; VENEZUELA;

AGE DISTRIBUTION; HUMANS; INCIDENCE; LATIN AMERICA; MENINGOCOCCAL INFECTIONS;

EID: 77951243175     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164110X12644252260754     Document Type: Review

References (50)

1. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001; 344: 1378-1388
2. Erickson LJ, de Wals P, McMahon J, et al. Complications of meningococcal disease in college students. Clin Infect Dis 2001; 33: 737-739 (Pubitemid 32762952)
3. Manchanda V, Gupta S, Bhalla P. Meningococcal disease: History, epidemiology, pathogenesis, clinical manifestations, diagnosis, antimicrobial susceptibility and prevention. Indian J Med Microbiol 2006; 24: 7-19
4. Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 2006; 19: 142-164 (Pubitemid 43157651)
5. Pan American Health Organization. Situación Actual de la Vigilancia de la Enfermedad Meningocócica en la Región de las Américas, CDC-PAHO/Dpc/Cd/A/482, Washington, DC: 2007: pp. 2-23
6. Granoff DM, Harrison LH, Borrow R. Meningococcal vaccines. In: Plotkin S, Orenstein WA, eds. Vaccines, 5th edn, Philadelphia, PA: Elsevier, 2008; pp. 399-434
7. American Academy of Pediatrics. Meningococcal infections. In: Pickering LK, ed. Red Book: Report of the Committee on Infectious Diseases, 27th edn, Elk Grove Village, IL: American Academy of Pediatrics, 2006; pp. 452-460
8. Stephens D. Conquering the meningococcus. FEMS Microbiol Rev 2007; 31: 3-14 (Pubitemid 46058815)
9. Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000; 287: 1816-1820
10. Stephens D, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia and Neisseria meningitidis. Lancet 2007; 369: 2196-2210 (Pubitemid 46977462)
11. World Health Organization. Control of Epidemic Meningococcal Disease: WHO Practical Guidelines, Lyon: Edition Foundation Marcel Mérieux, 1995: pp. 1-84
12. Bilukha OO, Rosestein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2005; 54: 1-21
13. Peltola, Kataja MA, Makela PH. Shift in the age-distribution of meningococcal disease as predictor of an epidemic? Lancet 1982; 2: 595-597 (Pubitemid 12049494)
14. Pollard A. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 2004; 23 (12 Suppl.): S274-S279 (Pubitemid 44544509)
15. Pan American Health Organization. Informe Regional de SIREVA II: Datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis, en procesos invasores, 2000-2005. Documentos Técnicos, Tecnologías Esenciales de Salud. THS/EV. 2007/002, Washington, DC: Pan American Health Organization, 2007. Available at: http://www.paho.org/Spanish/ AD/THS/EV/ LABS-Sireva.pdf[May 2008]
16. Pan American Health Organization. Informe Regional de SIREVA II: Datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis, en procesos invasores, 2006. OPS. Documentos Técnicos, Tecnologías Esenciales de Salud. THR/EV. 2008/001. Washington, DC: Pan American Health Organization. Available at: http://www.paho.org/spanish/AD/THS/ EV/labs- Sireva-II-2006.pdf[May 2008]
17. Ministry of Health. Health surveillance, Brazil. Available at: http:// portal.saude.gov.br/portal/saude/area.cfm?id-area5962[May 2008]
18. Sá fadi MA, Barros AP. Meningococcal conjugate vaccines: Efficacy and new combinations. J Pediatr (Rio J) 2006; 82 (3 Suppl.): S35-S44
19. Pírez MC, Picón T, Galazka J, et al. Control de un brote epidémico de enfermedad meningocó cica por N. meningitidis serogrupo B. Rev Med Uruguay 2004; 20: 92-101
20. Epidemiology of meningococcal disease in Chile. Available at http://epi.minsal.cl/epi/html/bolets/reportes/Meningitis/meningitis. pdf[June 2008]
21. Ministry of Health, Venezuela. Epidemiology. Available at: http:// www.mpps.gob.ve/ms/index.php[July 2008]
22. Pereira CS, Regueira M, Mollerach M. PorA types in Neisseria meningitidis serogroup B isolated in Argentina from 2001 to 2003: Implications for the design of an outer membrane protein-based vaccine. J Med Microbiol 2008; 57: 338-342 (Pubitemid 351358537)
23. National Institute of Health (Colombia). Public Health Surveillance System (SIVIGILA). Available at: http://www.ins.- gov.co/pdf/vcsp/Tablas/2006/ 2006-semana-52.pdf[July 2008]
24. Lemos AP, Brandão AP, Gorla MC, et al. Phenotypic characterization of Neisseria meningitidis strains isolated from invasive diseases in Brazil from 1999 to 2001. J Med Microbiol 2006; 55: 751-757
25. de Filippis I, de Andrade CF, Silva L, et al. PorA variable antigenic regions VR1, VR2, and VR3 of Neisseria meningitidis serogroups B and C isolated in Brazil from 1999 to 2004. Infect Immun 2007; 75: 3683-3685
26. Lemos AP, Yara T, Gorla MC, et al. Clonal distribution of invasive Neisseria meningitidis serogroup C strains circulating from 1976 to 2005 in Greater São Paulo, Brazil. J Clin Microbiol 2007; 45: 1266-1273 (Pubitemid 46626496)
27. Epidemiologic Surveillance Center (Brazil). Respiratory transmitted diseases. Available at: http://www.cve.saude.sp.gov.br[May 2008]
28. Barroso DE, Rebelo MC. Recognition of the epidemiological significance of Neisseria meningitidis capsular serogroup W135 in the Rio de Janeiro region, Brazil. Mem Inst Oswaldo Cruz 2007; 102: 773-775
29. Weidlich L, Baethgen L, Mayer L. High prevalence of Neisseria meningitidis hypervirulent lineages and emergence of W135:P1.5,2: ST-11 clone in Southern Brazil. J Infect 2008; 57: 324-331
30. Argentinean Society of Pediatrics. Bacterial meningitis and meningococcal disease. Infectious Diseases National Committee. Available at: http://www.sap.org.ar/staticfiles/comunicaciones/ menin2008.pdf[June 2008]
31. Efron AM, Sorhouet C, Salcedo C, et al. Significant increase of serogroup W135 invasive Neisseria meningitidis strains in Argentina: A new epidemiological feature on the region. Abstract 169. Presented at the 16th International Pathogenic Neisseria Conference, 2008, Rotterdam, The Netherlands
32. Chiavetta L, Chaves E, Ruzic A, et al. Vigilancia de Neisseria meningitidis en Argentina, 1993-2005: Distribución de serogrupos, serotipos y serosubtipos causantes de enfermedad invasiva. Rev Argent Microbiol 2007; 39: 21-27 (Pubitemid 46725181)
33. Agudelo CI, Sanabria OM, Ovalle MV. Serogroup Y meningococcal disease, Colombia. Emerg Infect Dis 2008; 14: 990-991
34. Morbidity Epidemiologic Information. DGEPI, Health Ministry, Mexico. Available at: http://www.dgepi.salud.gob.mx[May 2008]
35. Danzig L. Meningococcal vaccines. Pediatr Infect Dis J 2004; 23 (12 Suppl.): S285-S292 (Pubitemid 44544511)
36. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunization campaign against meningococcal serogroup C disease in UK: A success story. Vaccine 2001; 20 (Suppl. 1): S58-S67 (Pubitemid 32925012)
37. Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol 2002; 51: 717-722
38. Cano R, Larrauri A, Mateo S, et al. Impact of the meningococcal C conjugate vaccine in Spain: An epidemiological and microbiological decision. Euro Surveill 2004; 9: 5-6
39. Wiese-Posselt M, Hellenbrand W, Siedler A, et al. Universal childhood immunisation with pneumococcal vaccine and meningococcal serogroup C vaccine introduced in Germany. Euro Surveill 2006; 11: 3041
40. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364: 365-367 (Pubitemid 38970013)
41. Snape MD, Polllard AJ. Meningococcal polysaccharide proteinconjugate vaccines. Lancet Infect Dis 2005; 5: 21-30
42. Ramsay ME, Andrews NJ, Trotter CL, et al. Immunity from meningococcal serogroup C conjugate vaccination in England: Database analysis. BMJ 2003; 326: 365-366
43. Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002; 359: 1829-1831
44. Department of Health, UK. Changes to the routine childhood immunisation, 8 February, 2006. Available at: http://www.dh.gov. uk/PublicationsAndStatistics/ LettersAndCirculars/ DearColleagueLetters/fs/en[accessed May 2008]
45. Greeff, SC,Melker HE, Spanjaard L, et al. Protection from routine vaccination at the age of 14 months with meningococcal serogroup c conjugate vaccine in the Netherlands. Pediatr Infect Dis J 2006; 25: 79-80 (Pubitemid 43361483)
46. National Advisory Committee on Immunization (NACI). Statement on conjugate meningococcal vaccine for serogroups A, C, Y and W135. Can Commun Dis Rep 2007; 33: 1-24
47. Snape MD, Perrett KP, Ford KJ, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: A randomized controlled trial. JAMA 2008; 299: 173-184
48. Moe GR, Dave A, Granoff DM. Molecular analysis of anti-Npropionyl Neisseria meningitidis group B polysaccharide monoclonal antibodies. Mol Immunol 2005; 43: 1424-1431 (Pubitemid 43356382)
49. Miller E, Pollard AJ, Borrow R, et al. Safety and Immunogenicity of Novartis meningococcal serogroup B vaccine after three doses administered in infancy. Abstract 133. Presented at the 26th Annual Meeting of the European Society of Paediatric Infectious Diseases, 2008, Graz, Austria
50. de Wals P, Trottier P, Pepin J. Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: A model-based evaluation. Vaccine 2006; 24: 3500-3504